Payers Create CAR-T Approval Systems as Adoption Increases

Spurred by CMS’s decision to cover chimeric antigen receptor T-cell therapies under Medicare, commercial payers are beginning to systematize approvals for CAR-T treatment as use of these breakthrough cancer therapies is beginning to ramp up, experts say.

“Despite the costs of CAR-T, I know many plans were already looking at providing coverage prior to the CMS decision,” which was released in October 2019, says Dan Danielson, R.Ph., senior director of the access experience team at PRECISIONvalue. “CMS’s decision provided confirmation that they were on the right track,” he tells AIS Health, a division of MMIT.

Following the CMS changes, many health plans subsequently updated their medical necessity guidelines around T-cell therapies, adds Ashraf Shehata, national sector lead for life sciences at KPMG.

Case History Will Drive Authorizations

“There’s probably some space between case-by-case approvals and what I would call process-based approvals,” Shehata tells AIS Health. “They still need quite a bit of documentation. They have to make sure that the person has no prior treatment with CAR-T, proper organ function, no active infection, no history of allergies around stem cell transplant. And then we’ve seen a lot more visibility on the approvals of the treatment facility itself. Those parts of the process have been much more consistent.”

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

white-house
May 26

Biden Administration Has Options for Drug Pricing Reform

READ MORE
pharmacist-and-patient
May 26

Court Decision on Accumulator Rule Could Encourage State Bans

READ MORE
doctor-and-infusion-patient
May 26

Third-Party Care Pathways Gain Steam as Cancer Costs Rise

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today